Phages are microscopic viruses that have the remarkable ability to infect and eliminate bacteria. Phage-based veterinary vaccines harness these unique viruses to deliver specific pathogen antigens, prompting the immune system to generate a targeted immune response against the pathogen, which offers a high degree of specificity and versatility in veterinary vaccine design. BioVenic specializes in phage-based veterinary vaccine development, granting you access to cutting-edge vaccine technology platforms that hold great promise for advancing animal health.
Phage-based Veterinary Vaccine Development Platforms
Presently, there are two primary categories of phage-based veterinary vaccines well-established in the field, phage display vaccines and phage DNA vaccines. The convergence of these two strategies has given rise to a third approach known as hybrid phage vaccines. BioVenic provides development platforms for these vaccine types, allowing you the flexibility to select the one that aligns best with your specific project needs and preferences.
|
Platforms
|
Description
|
Advantages
|
Limitations
|
|
Phage Display Veterinary Vaccine
|
Using phage as a carrier, by integrating exogenous peptide or protein genes into phage genes, they are displayed as fusion proteins on the surface of the phage.
|
-
T4-based vaccines do not require a cold chain for distribution.
|
-
Lack of active epitopes to trigger a meaningful immune response.
-
Large protein subunits are more difficult to display on phage particles.
|
|
Phage DNA Veterinary Vaccine
|
Eukaryotic promoter-driven genes encoding protective antigenic peptides or mimetic epitopes are integrated into the phage genome.
|
-
Allows gene expression and protein folding in eukaryotic cells.
-
Protects eukaryotic expression cassettes from degradation.
|
-
The genome length must be within the viral particle packaging limits.
|
|
Hybrid Phage Veterinary Vaccine
|
Generated by the combination of phage display and phage DNA vaccine.
|
/
|
/
|
Our Services
BioVenic provides a one-stop service for phage-based veterinary vaccine development, whether it is based on phage display technology, phage DNA technology or a combination of these two technologies, our top-notch team and professional technology help you realize your veterinary vaccine development needs.
Fig.1 Design and utilization of phage vaccines. 1
Some sequences in the phage genome, as vaccine components, can elicit inflammatory signaling by stimulating the TLR pathway in the immune system. This method can trigger a strong antigen-specific immune response. Care must be taken when using such adjuvants to ensure a balance of safety and efficacy. BioVenic provides adjuvant development services to consider combining phage-based veterinary vaccine components with other adjuvants or immunomodulatory substances to balance the immune response and mitigate adverse effects, and to assist you in dose optimization experiments, in an effort to achieve the goal of stimulating the immune response while minimizing the occurrence of adverse effects.
Phages are structurally stable in the gastrointestinal tract, but phages administered via the oral route may infect intestinal bacteria, possibly leading to ecological disorders. Infection and further replication of phages may induce the release of endotoxins from infected bacteria, increasing the risk of host damage. With our encapsulation and emulsification technologies, phage particles can be precisely encapsulated in polymer or liposome-encapsulated nanoparticles to meet the needs of specific formulations. This precise encapsulation process ensures that the phage is stabilized and maintains its activity. In addition, BioVenic customizes the formulation of phage-based veterinary vaccines based on different forms of administration, including liquid formulations and lyophilization techniques. This means that you can choose the most appropriate form of medicine for your specific situation to ensure effective vaccine delivery and immune response. Whether you need the convenience of a liquid vaccine or the long-term stability of lyophilization technology, BioVenic offers tailor-made solutions.
In Vivo and In Vitro Assessments
BioVenic offers comprehensive phage vaccine assessment services covering all aspects of in vivo and in vitro to ensure that your vaccine program can move forward successfully. BioVenic provides animal modeling services to evaluate the immunogenicity, safety and efficacy of phage-based veterinary vaccines. This includes experiments in different animal models such as mice, rats, and rabbits. We also provide in vitro immunology tests to evaluate the cellular and humoral immune response of vaccines to ensure that your vaccine is indeed highly immunogenic, and stability tests to ensure that vaccines remain active under different storage conditions for your subsequent use.
Why Choose Us?
Application of novel phage-related technologies to veterinary vaccine development.
Different types of phage platforms are available to meet your different needs.
We have established a one-stop phage-based veterinary vaccine development platform to provide you with more convenient services.
The phage-based veterinary vaccine is a new technology platform with a broad development prospect. BioVenic is ready to collaborate with you in the pursuit of scientific excellence. From phage display technology to assessment assays, we provide comprehensive services for veterinary vaccine development. Please do not hesitate to contact us and let's contribute to animal health and veterinary medicine!
References
-
Bao, Qing, et al. "Phage-based vaccines." Advanced drug delivery reviews 145 (2019): 40-56.
-
Hess, Krystina L., and Christopher M. Jewell. "Phage display as a tool for vaccine and immunotherapy development." Bioengineering & Translational Medicine 5.1 (2020): e10142.
-
Palma, Marco. "Aspects of Phage-Based Vaccines for Protein and Epitope Immunization." Vaccines 11.2 (2023): 436.
